We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Blood Test Predicts Personalized Depression Treatment

By LabMedica International staff writers
Posted on 22 Jun 2016
A blood test has been developed that accurately and reliably predicts whether depressed patients will respond to common antidepressants, which could herald a new era of personalized treatment for people with depression.

Guided by this test, patients with blood inflammation above a certain threshold could be directed towards earlier access to more assertive antidepressant strategies, such as a combination of antidepressants, before their condition worsens.

Scientists at King’s College London (UK) focused on two biomarkers in the blood that measure inflammation, as previous studies have already shown that elevated levels of inflammation are associated with poor response to antidepressants. More...
They measured the quantity of two biomarkers, Macrophage Migration Inhibitory Factor (MIF) and interleukin (IL)-1β, in two independent clinical samples of depressed patients, before or after they took a range of commonly prescribed antidepressants.

The ribonucleic acid (RNA) quantity was assessed by evaluation of the A260/280 and A260/230 ratios using a Nanodrop spectrometer (NanoDrop Technologies, Wilmington, DE, USA), and RNA quality was determined using an Agilent Bioanalyzer (Agilent Technologies, Santa Clara, CA, USA). RNA samples were then stored at -80 °C until their processing for gene expression analyses.

The investigators r found that blood test results above a specified threshold level could precisely and reliably predict the probability of individuals responding to the treatments. Patients with levels of MIF and IL-1β above the thresholds showed a 100% chance of not responding to conventional, commonly prescribed antidepressants. Those with inflammation below the suggested threshold could be expected to respond to first-line antidepressants.

The two biomarkers examined in the study are both thought to be important in predicting how people with depression respond to antidepressants, as they are involved in several brain mechanisms relevant to depression. These include the birth of new brain cells and connections between them, as well as the death of brain cells through a process called oxidative stress. Oxidative stress occurs when the body both overproduces and then struggles to remove molecules called free radicals. These free radicals break down brain connections and disrupt the brain's chemical signaling, which in turn can lead to the development of depressive symptoms by reducing the brain's protective mechanisms.

Annamaria Cattaneo, PhD, the senior author of the study, said, “'This is the first time a blood test has been used to precisely predict, in two independent clinical groups of depressed patients, the response to a range of commonly prescribed antidepressants. These results also confirm and extend the mounting evidence that high levels of inflammation induce a more severe form of depression, which is less likely to respond to common antidepressants.” The study was published on May 11, 2016, in the journal The International Journal of Neuropsychopharmacology.

Related Links:
King’s College London
NanoDrop Technologies
Agilent Technologies

New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
Serological Pipet Controller
PIPETBOY GENIUS
New
Silver Member
Quality Control Material
NATtrol Chlamydia trachomatis Positive Control
New
Rapid Test Reader
DIA5000
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The ONC IN-CYT platform leverages cross indication biomarker cyto-signatures (Photo courtesy of OraLiva)

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer

Each year, 54,000 Americans are diagnosed with oral cancer, yet only 28% of cases are identified at an early stage, when the five-year survival rate exceeds 85%. Most diagnoses occur in later stages, when... Read more

Hematology

view channel
Image: The microfluidic device for passive separation of platelet-rich plasma from whole blood (Photo courtesy of University of the Basque Country)

Portable and Disposable Device Obtains Platelet-Rich Plasma Without Complex Equipment

Platelet-rich plasma (PRP) plays a crucial role in regenerative medicine due to its ability to accelerate healing and repair tissue. However, obtaining PRP traditionally requires expensive centrifugation... Read more

Pathology

view channel
Image: Researchers have developed a novel method to analyze tumor growth rates (Photo courtesy of Adobe Stock)

Novel Method To Analyze Tumor Growth Rates Helps Tracks Progression Between Diagnosis and Surgery

Patients diagnosed with breast cancer often worry about how quickly their tumors grow while they wait for surgery, and whether delays in treatment might allow the disease to spread beyond the point of cure.... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.